Secondary analysis of enzalutamide and PSA-levels in metastatic prostate cancer in the ARCHES randomized clinical trial
Prof. Andrew Armstrong
In men with metastatic hormone-sensitive prostate cancer (mHSPC), PSA decline after treatment has been associated with improved survival. However, the data on PSA decline are limited in men with mHSPC after treatment with enzalutamide plus androgen deprivation therapy (ADT). Secondary analysis of the multinational randomized phase 3 ARCHES trial found that those who received enzalutamide plus ADT versus placebo plus ADT had improved clinical outcomes, irrespective of PSA level at enrollment. Achieving undetectable PSA after treatment with enzalutamide plus ADT was associated with improved clinical outcomes.
